BOARD OF DIRECTORS


 
David Barry.png

David Berry, M.D., Ph.D.
General Partner, Flagship Pioneering

Dr. Berry joined Flagship Pioneering in 2005, and serves as a General Partner, focusing on conceiving, creating, resourcing, and launching groundbreaking companies. Dr. Berry has co-founded more than 20 companies across life sciences and sustainability, and served as founding CEO of over 10 of them. 

He has been broadly recognized as a world-leading innovator: elected as a Young Global Leader by the World Economic Forum, named as Innovator of the Year by MIT Technology Review from amongst its annual TR35 list, and selected as one of 12 Innovators Reshaping Reality by the U.S. State Department. 

A member of its Founding Leadership Council, Dr. Berry currently serves on the United Nations Sustainable Development Solutions Network (UN SDSN), where he has been involved with the development and implementation of the Sustainable Development Goals (SDGs). He previously served as a member of the Corporation of MIT and the Board of the Boston Philharmonic Orchestra, and is currently a board member of the Hackley School. 

Dr. Berry received his M.D. from Harvard Medical School and his Ph.D. from MIT in Biological Engineering through the Health Sciences and Technology program, completing the fastest dual degree in the modern history of the program, during which he was awarded the Lemelson-MIT Prize award for the most inventive and innovative student at MIT.


 
Claire Fraser.png

Claire M. Fraser, Ph.D.
Director of the Institute for Genome Sciences (University of Maryland School of Medicine in Baltimore)

Dr. Fraser is Director of the Institute for Genome Sciences (University of Maryland School of Medicine in Baltimore), and has joint faculty appointments at the University of Maryland School of Medicine in the Department of Medicine and Microbiology/Immunology. 

Until 2007, she was President and Director of The Institute for Genomic Research (TIGR) in Rockville, MD, and led the teams that sequenced the genomes of several microbial organisms, including important human and animal pathogens. She helped launch the new field of microbial genomics and revolutionized the way microbiology has been studied. Her work with the FBI on the Amerithrax investigation (2001-2008) led to the identification of four genetic mutations in the anthrax spores, allowing the FBI to trace the material back to its original source. 

Dr. Fraser has authored over 300 publications and served on the editorial boards of nine scientific journals. She has served on advisory panels for all of the major Federal funding agencies, the National Research Council, the Department of Defense, and the intelligence community. Since 2006, she has also served as a member of the board of directors of Becton, Dickinson and Company (BD).  

Dr. Fraser received her B.S. degree in Biology from Rensselaer Polytechnic Institute and her Ph.D. degree in Pharmacology at the State University of New York at Buffalo.


 
John Mendlein.png

John Mendlein, Ph.D., J.D.
Executive Partner, Flagship Pioneering

Dr. Mendlein joined Flagship Pioneering as Executive Partner in February 2019. A longtime member of Flagship’s broader ecosystem of companies, Dr. Mendlein is an experienced biotech leader and has served in numerous executive and board roles. He contributes to Flagship’s strategic and operational objectives, including the origination of new Flagship Labs companies, serves on the boards of Flagship’s companies, and works with portfolio company CEOs and their teams to achieve the best attainable value for each organization.

Prior to joining Flagship, Dr. Mendlein served as President of Corporate and Product Strategy at Moderna Therapeutics. He led the cross-functional team responsible for ensuring Moderna’s readiness for its initial public offering in 2018, and was a member of its board of directors from 2012-2018.

During his career, Dr. Mendlein has served as Chief Knowledge Officer, General Counsel, and board member at Aurora Biosciences; CEO of Adnexus Therapeutics; Executive Chairman, Founder, and Interim CEO of Fate Therapeutics; and Executive Chairman and CEO of Affinium Pharmaceuticals. He is a founder and board member of Homes for Sudan, a non-profit in Boston, MA, and a scientific advisory board member for Ocean Discovery Institute, a non-profit in San Diego, CA. He has served on the boards of the Biotechnology Innovation Organization, as well as on three of Flagship’s companies: Moderna, Axcella Health and Editas Medicine.

Dr. Mendlein holds a Ph.D. in Physiology and Biophysics from the University of California, Los Angeles, a J.D. from the University of California, Hastings College of the Law, and a B.S. in Biology from the University of Miami.


 
Mike Rosenblatt.png

Michael Rosenblatt, M.D.
Chief Medical Officer, Flagship Pioneering

Dr. Rosenblatt joined Flagship Pioneering in 2016, assuming the newly created position of Chief Medical Officer, leading global clinical development and medical affairs and playing a key role in Flagship’s venture creation as well as serving as an ongoing strategic resource for all Flagship companies. Additionally, he will serve on the board of directors of several portfolio companies and is currently a board member of Rubius Therapeutics. 

He joined Flagship from Merck, where he was Executive Vice President and Chief Medical Officer from 2009 to 2016. During his career, Dr. Rosenblatt has served as Dean of Tufts University School of Medicine; Ebert Professor of Molecular Medicine and Minot Professor of Medicine, both at Harvard Medical School; President, Beth Israel Deaconess Medical Center; and Director of the Harvard-MIT Division of Health Sciences and Technology. 

In 1981, Dr. Rosenblatt was named Chief of the Endocrine Unit at Massachusetts General Hospital. He was Senior Vice President for research at Merck, beginning in 1984, where he co-led worldwide development of alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis, and has served as a founding scientist, scientific advisory board member, or director of more than a dozen biopharmaceutical companies. He is a member of the Harvard Medical School Board of Fellows, and the research advisory committees of the Massachusetts General Hospital, and the Brigham and Women’s Hospital. 

Dr. Rosenblatt received his A.B. summa cum laude from Columbia and M.D. magna cum laude from Harvard. His internship, residency and endocrinology training were all at the Massachusetts General Hospital.


 
Amber Salzman.png

Amber Salzman, Ph.D.
President and CEO

Dr. Salzman is the President and CEO of Ohana Biosciences. She previously served as the President and CEO at Adverum Biotechnologies, and was a Co-Founder of Annapurna Therapeutics SAS where she served as its President and CEO prior to its merger with Avalanche Biosciences to create Adverum Biotechnologies.

Prior to her role at Adverum Biotechnologies, Dr. Salzman served as President and CEO of Cardiokine, Inc. until it was acquired by Cornerstone Therapeutics. Prior to that, she was a member of the GlaxoSmithKline (GSK) research and development executive team, where she was responsible for Operations for Medicine Development across therapeutic areas, planning and managing drug development projects and clinical trials with over 30,000 active patients around the world.

In addition to her roles in industry, Dr. Salzman is the President of the Stop ALD Foundation, a Medical Research Foundation dedicated to finding better therapies for people with adrenoleukodystrophy and advocating on behalf of patients with rare diseases. She was instrumental in establishing the first gene therapy human proof of concept for ALD and adding ALD to the national recommended list of diseases for which newborns should be screened.

Additionally, she serves on the Boards of Lankenau Institute of Medical Research and Drexel University Dornsife School of Public Health.

Dr. Salzman received her Bachelor's degree from Temple University and holds a Ph.D. in Mathematics from Bryn Mawr College. Honors include being inducted into Temple University's League of Entrepreneurial Women Hall of Fame.


 
Greg Summe.png

Gregory L. Summe, M.S., MBA
Managing Partner, Glen Capital Partners

Mr. Summe is the Managing Partner of Glen Capital Partners, a value-oriented hedge fund, which he founded in 2014. Mr. Summe was the Managing Director and Vice Chairman of Global Buyout at The Carlyle Group from 2009 to 2014. Prior to joining Carlyle, he was the Chairman and CEO of PerkinElmer, Inc., a global leader in health sciences, which he led from 1998 to 2009. He also served as a senior advisor to Goldman Sachs Capital Partners from 2008 to 2009. 

Prior to PerkinElmer, Mr. Summe was with AlliedSignal, now Honeywell International, serving as the President of General Aviation Avionics, President of the Aerospace Engines Group and President of the Automotive Products Group. Before joining AlliedSignal, he was the General Manager of Commercial Motors at General Electric and was a partner with McKinsey & Company, Inc. 

Mr. Summe holds B.S. and M.S. degrees in Electrical Engineering from the University of Kentucky and the University of Cincinnati, and an MBA with distinction from the Wharton School at the University of Pennsylvania. He is in the Engineering Hall of Distinction at the University of Kentucky. He also serves on the board of directors of the State Street Corporation, NXP Semiconductors NV, and Pella Corporation.